Suara.com – Previously deemed unnecessary and ineffective, the World Health Organization (WHO) again recommend treatment antibody synthetic Regeneron for Covid-19. However, this recommendation is only for patients with certain health profiles.
Launching from Healthshots, people with non-severe Covid-19 who remain at high risk of hospitalization can use the antibody combo, as can critically ill patients who are unable to mount an adequate immune response. This is stated in the WHO findings, published in BMJ.
Regeneron is the third treatment for Covid-19 recommended by global health authorities.
The Regeneron cocktail of synthetic antibodies casirivimab and imdevimab has been found to reduce the risk of hospitalization for unvaccinated, elderly or immunosuppressed Covid patients. This is stated by the reports of three clinical trials that have not been peer reviewed.
Also Read:
A number of pregnant women in Balikpapan are afraid of getting vaccinated, the reason?
“For all other Covid-19 patients, any benefit from this antibody treatment is likely to be negligible,” concludes WHO
Designed by biotech company Regeneron and marketed by pharmaceutical giant Roche under the name Ronapreve, the treatment was given to former US President Donald Trump as he faced corona virus.
When used together, the monoclonal antibodies casirivimab and imdevimab bind to the SARS-CoV-2 spike protein, neutralizing the virus’ ability to infect cells.
In July, Japan became the first country to fully approve Regeneron antibody treatment for patients with mild to moderate Covid-19.
Antibody combinations have been authorized for emergency or temporary pandemic use in a number of countries and regions, including the European Union, United States, India, Switzerland and Canada.
– .
